Search Technologies
Displaying 61 - 70 of 83 results
Researchers at the University of Maryland have created hundreds of innovations that are available for licensing. Our Discovery Portfolio contains an exciting mix of vaccines, drug targets, therapeutics, devices and cutting edge techniques that promise to make a quantifiable impact on human health and the environment.
Search by keyword:
-
Plasmid maintenance system for antigen delivery
Published Wednesday, May 28, 2014For live bacterial vaccines, various plasmid-based expression technologies may be utilized to express foreign antigens from the host bacteria. Keys to success using such systems include the need to achieve adequate antigen production to generate a good immune response, while reducing toxicity that may be associated with the foreign protein, and...
Investigator(s): James Galen
Categories: Therapeutics, Vaccines
Keyword(s): vaccine
Docket: JG-98-002
-
PSA peptides for prostate cancer immunotherapy
Published Wednesday, May 28, 2014Prostate Specific Antigen (PSA) is a protein produced solely by prostate tissue, including tumors, and is considered a promising target for development of a prostate cancer vaccine. In fact, other groups are currently developing candidate vaccines focused on Class I-restricted CD8+ T-cell immunity, but the ultimate success of those efforts is...
Investigator(s): Richard Alexander, Elena Klyushnenkova, Arthur Vandenbark, Jason Link
Categories: Therapeutics, Biologics, Vaccines
Keyword(s): prostate cancer
Docket: RA-2004-035
-
Novel Opioid Analgesics With Reduced Tolerance
Published Wednesday, May 28, 2014UMB 425 is a novel opioid with bi-functional activity that combines a delta-opioid antagonist and a mu-opioid agonist in a single compound with antinociceptive effects comparable to morphine. With reduced tolerance liabilities, UMB 425 provides a novel therapeutic approach in the treatment of patients who suffer from chronic pain with...
Investigator(s): Andrew Coop, Alexander MacKerell, Rae R. Matsumoto
Categories: Therapeutics, Small molecules
Keyword(s): Opioid, tolerance, analgesic
Docket: AC-2013-055
-
Natural TFD-Containing Compound Prevents Tumorigenesis
Published Wednesday, May 28, 2014In 2011, prostate cancer was the second leading cause of cancer deaths in men and accounted for approximately a third of all new cases of cancer in the United States. Hormone therapy is the treatment of choice in cases where the primary tumor has metastasized or has advanced to a high-grade, high-risk disease. However, alternative strategies...
Investigator(s): Hafiz Ahmed, Prasan Guha, Engin Kaptan, Gerardo R. Vasta, Gargi Benerjee
Categories: Therapeutics
Keyword(s): natural products
Docket: HA-2011-053
-
Multivalent Vaccine Against Staphylococcus Aureus
Published Wednesday, May 28, 2014There are nearly 2 million healthcare-associated infections in the U.S. per year, according to CDC-reported statistics. Many of these infections are due to colonization of implantable medical devices with drug-resistant forms of bacteria such as methicillin-resistant Staphylococcus aureus (MRSA). The increasing incidence, morbidity and...
Investigator(s): Mark E. Shirtliff, Jan M. Harro, Jeffrey G. Leid, Rebecca Brady, Graeme O'May
Categories: Therapeutics, Vaccines
Keyword(s): vaccine, staph, Biofilm, MRSA
Docket: MS-2012-065
-
Microcin H47 Plasmid Selection System
Published Wednesday, May 28, 2014The inventors engineered a novel stabilized plasmid selection system incorporating the gene mchI, conferring immunity against a natural antimicrobial peptide called microcin H47, which can be incorporated into the bacterial growth medium. There are no known clinical uses for microcin H47, so this approach is expected to meet vaccine regulatory...
Investigator(s): James Galen, Chee-Mun Fang
Categories: Therapeutics, Vaccines
Keyword(s): vaccine, Microcin
Docket: JG-2007-005
-
Methylated Peptides Derived from Tau Protein and Their Antibodies for Diagnosis and Therapy of Alzheimer's Disease
Published Wednesday, May 28, 2014Alzheimer's disease (AD) is a neurologically degenerative disease that is defined in part by the accumulation of aberrant tau proteins (neurofibrillary tangles) within the brain. The mechanisms which drive tau aggregation is not fully understood and existing treatments do little to delay the inevitable decline of Alzheimer's patients. UMB...
Investigator(s): Jyanyu Austin Yang, Stefani N. Thomas, Jeffrey A. Kuret, Kristen E. Funk
Categories: Diagnostics, Therapeutics
Keyword(s): Alzheimer, AD
Docket: AY-2012-036
-
Methods of treating obstructive lung diseases using bitter tastants
Published Wednesday, May 28, 2014Asthma, an obstructive lung disease and the most common chronic condition among young children, affects ~20 million Americans, causing more than 4,000 deaths each year. Researchers have discovered a method for treating asthma and related obstructive lung diseases using bitter taste agonists as bronchodilators. This invention was made possible...
Investigator(s): Stephen Liggett, Deepak Deshpande, Wayne Wang
Categories: Therapeutics
Keyword(s): lung diseases, asthma, chronic
Docket: SL-2010-062
-
Methods for Regulating Urinary Potassium
Published Wednesday, May 28, 2014Potassium is the most abundant intracellular cation. It is critically important for many physiologic processes, including maintenance of cellular membrane potential, homeostasis of cell volume, and transmission of action potentials in nerve cells. Small changes in the extracellular potassium level can have profound effects on the function of...
Investigator(s): Paul Welling, Liang Feng
Categories: Therapeutics, Small molecules, Biologics
Keyword(s): Urinary Potassium, potassium
Docket: PW-2008-072
-
Melanoma Oncolytic Virotherapy by the HSV-2 Mutant delta-PK
Published Wednesday, May 28, 2014Oncolytic viruses are replication-conditional viruses with relative tumor selectivity and are a therapeutic strategy designed to reduce tumor burden by direct cell lysis; however, their modest clinical efficacy may be related to poor virus replication within the tumors. The present invention is based on the hypothesis that virotherapy...
Investigator(s): Laure Aurelian, Aric Colunga, Jennifer Laing
Categories: Therapeutics, Biologics
Keyword(s): Melanoma, Virotherapy
Docket: LA-2009-096